Immunocore Holdings plc
(NASDAQ: IMCR)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $36.02 | Change: +1.22 | %Change: +3.51% | Volume: 283,322 |
Open: | $ 35.00 | Volume: | 283,322 | |
---|---|---|---|---|
High: | $ 36.31 | Yield(%) | 0.00 | |
Low: | $ 34.68 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 1.74B | |
EPS ($) | -1.20 | Shares Out: | 50.01M |
% Price Change (last 4 weeks): | -19.65 |
---|---|
% Price Change (last 13 weeks): | -45.18 |
% Price Change (last 26 weeks): | -51.42 |
% Price Change (last 52 weeks): | -40.57 |
% Price Change (year to date): | -49.06 |
Return on Equity (%): | -15.76 |
---|---|
Return on Assets (%): | -9.90 |
Return on Invested Capital (%): | -68.84 |
Gross Profit Margin (%): | 97.94 |
---|---|
Net Profit Margin (%): | -22.17 |
Operating Profit Margin (%): | -23.91 |
|
|
50-day Moving Average: | $48.03 |
---|---|
200-day Moving Average: | $56.55 |
Avg. Daily Vol. (last 50 days): | 874,763 |
Avg. Daily Vol. (last 200 days): | 524,619 |
52-wk high: | $76.98 |
52-wk low: | $33.05 |
Bid: | $33.08 |
Ask: | $36.58 |
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
|
Immunocore Holdings plc
92 Park Drive Milton Park Abingdon OX OX14 4RY Phone: 44.1235.438600 Fax: n/a http://www.immunocore.com |
Earnings (1year) ($): | n/a |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 7.37 |
Cash Flow ($): | -1.03 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 13.34 |
Price/Book (x): | 9.26 |
Price/Cash Flow (x): | 1131.70 |
Quick Ratio (x): | 3.77 |
---|---|
Current Ratio (x): | 3.80 |
LT Debt/Equity (x): | 22.41 |
Total Debt/Equity (x): | 22.78 |